These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32578152)

  • 1. Brain
    Kucharczak F; Suau M; Strauss O; Ben Bouallègue F; Mariano-Goulart D
    Ann Nucl Med; 2020 Aug; 34(8):565-574. PubMed ID: 32578152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting the most relevant brain regions to discriminate Alzheimer's disease patients from healthy controls using multiple kernel learning: A comparison across functional and structural imaging modalities and atlases.
    Rondina JM; Ferreira LK; de Souza Duran FL; Kubo R; Ono CR; Leite CC; Smid J; Nitrini R; Buchpiguel CA; Busatto GF
    Neuroimage Clin; 2018; 17():628-641. PubMed ID: 29234599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of synthetic PET images of synaptic density and amyloid from
    Wang R; Liu H; Toyonaga T; Shi L; Wu J; Onofrey JA; Tsai YJ; Naganawa M; Ma T; Liu Y; Chen MK; Mecca AP; O'Dell RS; van Dyck CH; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5115-5129. PubMed ID: 34224153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging.
    Akamatsu G; Ikari Y; Nishio T; Nishida H; Ohnishi A; Aita K; Sasaki M; Sasaki M; Senda M
    Ann Nucl Med; 2016 Jan; 30(1):18-28. PubMed ID: 26337533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.
    Ng S; Villemagne VL; Berlangieri S; Lee ST; Cherk M; Gong SJ; Ackermann U; Saunder T; Tochon-Danguy H; Jones G; Smith C; O'Keefe G; Masters CL; Rowe CC
    J Nucl Med; 2007 Apr; 48(4):547-52. PubMed ID: 17401090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease.
    Musiek ES; Saboury B; Mishra S; Chen Y; Reddin JS; Newberg AB; Udupa JK; Detre JA; Hofheinz F; Torigian D; Alavi A
    Hell J Nucl Med; 2012; 15(3):190-6. PubMed ID: 23106049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image reconstruction methods affect software-aided assessment of pathologies of [
    Lindström E; Oddstig J; Danfors T; Jögi J; Hansson O; Lubberink M
    Neuroimage Clin; 2020; 28():102386. PubMed ID: 32882645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and comparative evaluation of different activity detection methods in brain FDG-PET.
    Buchholz HG; Wenzel F; Gartenschläger M; Thiele F; Young S; Reuss S; Schreckenberger M
    Biomed Eng Online; 2015 Aug; 14():79. PubMed ID: 26281849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.
    Kawachi T; Ishii K; Sakamoto S; Sasaki M; Mori T; Yamashita F; Matsuda H; Mori E
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):801-9. PubMed ID: 16550383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of different examination conditions on image quality and quantitative value of amyloid positron emission tomography using
    Otani T; Otsuka H; Matsushita K; Otomi Y; Kunikane Y; Azane S; Amano M; Harada M; Miyoshi H
    Ann Nucl Med; 2021 Sep; 35(9):1004-1014. PubMed ID: 34046870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.
    Pagani M; De Carli F; Morbelli S; Öberg J; Chincarini A; Frisoni GB; Galluzzi S; Perneczky R; Drzezga A; van Berckel BN; Ossenkoppele R; Didic M; Guedj E; Brugnolo A; Picco A; Arnaldi D; Ferrara M; Buschiazzo A; Sambuceti G; Nobili F
    Neuroimage Clin; 2015; 7():34-42. PubMed ID: 25610765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
    Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
    Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Relevance of [
    Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease.
    Brugnolo A; De Carli F; Pagani M; Morbelli S; Jonsson C; Chincarini A; Frisoni GB; Galluzzi S; Perneczky R; Drzezga A; van Berckel BNM; Ossenkoppele R; Didic M; Guedj E; Arnaldi D; Massa F; Grazzini M; Pardini M; Mecocci P; Dottorini ME; Bauckneht M; Sambuceti G; Nobili F
    J Alzheimers Dis; 2019; 68(1):383-394. PubMed ID: 30776000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [
    Chiaravalloti A; Barbagallo G; Martorana A; Castellano AE; Ursini F; Schillaci O
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1796-1805. PubMed ID: 31201430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.